Alembic Pharmaceuticals through its joint venture firm Aleor Dermaceuticals has received USFDA approval for Desonide Ointment. The Desonide Ointment with a strength of 0.05 per cent, is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
The drug is therapeutically equivalent to the reference listed drug product, Desonide Ointment, 0.05, of Perrigo New York, Inc.
It has an estimated market size of USD 13 million for 12 months ending December 2018.
Company Profile : Alembic Pharmaceuticals Ltd